Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Contributed by: Business Wire

Tags

Alternative Medicine

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

neuroscience

More Like This

Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

(Photo: Business Wire)

ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

PR Newswire associated0

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder

First Cannabis full-spectrum product, manufactured in Brazil by Ease Labs, is approved by the local Health Regulatory Agency

PR Newswire associated0

Tetra Pharm Technologies and Glysious Announce Collaboration to Develop Transdermal Combination Drugs Targeting the Endocannabinoid System

Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases